Department of Radiology
Found 5 results
Filters: Author is Bander, Neil H  [Clear All Filters]
2023
Stangl-Kremser J, Sun M, Ho B, Thomas J, Nauseef JT, Osborne JR, Molina A, Sternberg CN, Nanus DM, Bander NH et al..  2023.  Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen targeted radionuclide therapy.. Prostate. 83(14):1351-1357.
Stangl-Kremser J, Ricaurte-Fajardo A, Subramanian K, Osborne JR, Sun M, Tagawa ST, Bander NH.  2023.  Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature.. Prostate. 83(10):901-911.
2016
Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, Chalasani S, Weber WA, Spratt DE, Veach DR et al..  2016.  Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling.. EJNMMI Res. 6(1):7.
2015
Pandit-Taskar N, O'Donoghue JA, Durack JC, Lyashchenko SK, Cheal SM, Beylergil V, Lefkowitz RA, Carrasquillo JA, Martinez DF, Fung AMak et al..  2015.  A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer.. Clin Cancer Res. 21(23):5277-85.
2014
Pandit-Taskar N, O'Donoghue JA, Beylergil V, Lyashchenko S, Ruan S, Solomon SB, Durack JC, Carrasquillo JA, Lefkowitz RA, Gönen M et al..  2014.  ⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.. Eur J Nucl Med Mol Imaging. 41(11):2093-105.